Category: 490021-97-1

On January 30, 2003, Bhalay, Gurdip; Howe, Trevor John; Le Grand, Darren Mark; Walker, Clive Victor published a patent.Electric Literature of 490021-97-1 The title of the patent was Preparation of azetidine-containing amides and their use as CCR-3 receptor antagonists. And the patent contained the following:

The invention relates to azetidine derivatives (I; variables defined below; e.g. (E)-N-[(S)-1-tert-butoxymethyl-3-[3-(4-fluorophenoxy)azetidin-1-yl]propyl]-3-(5-cyano-2-methoxyphenyl)acrylamide) in free or salt form. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described. The agents of the invention act as CCR-3 receptor antagonists, thereby inhibiting the infiltration and activation of inflammatory cells, particularly eosinophils, and inhibiting allergic response. The effect of agents of the invention on the binding of human eotaxin to human CCR-3 was determined Eighteen I have IC50 values <1 μM in the above assay. For instance, (E)-N-[(S)-1-tert-butoxymethyl-3-[3-(4-fluorophenoxy)azetidin-1-yl]propyl]-3-(5-cyano-2-methoxyphenyl)acrylamide has an IC50 value of 1 nM. Most of the 18 I exhibit selectivity for inhibition of CCR-3 binding relative to inhibition of binding of the alpha-1 adrenergic receptor. Eighteen example preparations of I are included. For example, the above I was prepared via intermediates [(S)-1-tert-butoxymethyl-3-iodopropyl]carbamic acid benzyl ester, [(S)-1-tert-butoxymethyl-3-[3-(4-fluorophenoxy)azetidin-1-yl]propyl]carbamic acid benzyl ester, and (S)-1-tert-butoxymethyl-3-[3-(4-fluorophenoxy)azetidin-1-yl]propylamine. For I: Ar1 is Ph substituted by ≥1 halogen atoms; Ar2 is Ph optionally substituted by ≥1 halogen, cyano, hydroxy, nitro, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-alkoxycarbonyl or di(C1-C8-alkyl)aminocarbonylmethoxy; R1 is H or C1-C8-alkyl optionally substituted by hydroxy, C1-C8-alkoxy, acyloxy, halogen, carboxy, C1-C8-alkoxycarbonyl, -N(R2)R3, -CON(R4)R5 or by a monovalent cyclic organic group having 3-15 atoms in the ring system. R2 and R3 are each independently H or C1-C8-alkyl, or R2 is H and R3 is hydroxy-C1-C8-alkyl, acyl, -SO2R6 or -CON(R4)R5, or R2 and R3 together with the N atom to which they are attached denote a 5- or 6-membered heterocyclic group; R4 and R5 are each independently H or C1-C8-alkyl, or R4 and R5 together with the N atom to which they are attached denote a 5- or 6-membered heterocyclic group; R6 is C1-C8-alkyl, C1-C8-haloalkyl, or Ph optionally substituted by C1-C8-alkyl; X is -C(O)-, -O- or -CH2-; and n is 1, 2, 3 or 4. The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).Electric Literature of 490021-97-1

The Article related to azetidine amide preparation ccr3 receptor antagonist, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.Electric Literature of 490021-97-1

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On September 25, 2003, Le Grand, Darren Mark; McCarthy, Clive; Walker, Clive Victor; Woods, John James published a patent.SDS of cas: 490021-97-1 The title of the patent was Preparation of azetidine derivatives as CCR-3 receptor antagonists. And the patent contained the following:

The title compounds [I; Ar = (un)substituted Ph; R1 = H, alkyl optionally substituted by OH, alkoxy, acyloxy, halo, CO2H, etc.; R2 = H, alkyl or cycloalkyl, and R3 = alkyl substituted by Ph, OPh, acyloxy or naphthyl, or R3 = cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5-11 ring atoms of which 1-4 are heteroatoms, (un)substituted Ph or naphthyl, or R2 and R3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5-10 ring atoms of which 1-3 are heteroatoms; X = CO, O, CH2, CH(OH); Y = O, S; m = 1-4; and n, p and q = 0, 1 (n+p+q = 1, 2; n+q = 1; p+q = 1; and when n = 0, p = 0)], useful for treating conditions mediated by CCR3, were prepared Thus, reacting (S)-2-amino-4-[3-(4-chlorophenoxy)azetidin-1-yl]butan-1-ol with 3,5-dimethoxyphenyl isocyanate in CH2Cl2 afforded the urea (S)-II which showed IC50 of 0.007 μM against CCR-3 binding. The exemplified compounds I generally have IC50 values below 1 μM in CCR-3 binding assay. Pharmaceutical compositions that contain the compounds I and processes for preparing the compounds are also described. The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).SDS of cas: 490021-97-1

The Article related to azetidine preparation ccr3 receptor antagonist, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.SDS of cas: 490021-97-1

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On March 24, 2005, Le Grand, Darren Mark published a patent.COA of Formula: C9H11Cl2NO The title of the patent was Preparation of 1,3-disubstituted azetidine derivatives for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases. And the patent contained the following:

Compounds of formula I and II [Ar = Ph optionally substituted by one or more substituents selected from halo, C1-C8-alkyl, cyano, nitro; X1 = S, S(O), S(O)2; X2 = C(O), O, CH2, S, S(O), S(O)2; m = 1, 2, 3, 4; R1 = H, C1-C8-alkyl optionally substituted; Q = C(Rb)(Rc) where Rb and Rc are independently C1-C8-alkyl or Rb and Rc together form a C3-C10-cycloalkyl; Y = O, S; R2 = H, C1-C8-alkyl, C3-C10-cycloalkyl; R3 = C1-C8-alkyl substituted by Ph, phenoxy, acyloxy, naphthyl, or R3 is C3-C10-cycloalkyl optionally having a benzo group, a heterocyclic group] were prepared and are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. E.g., 1-benzhydryl-3-(4-chlorophenylsulfanyl)azetidine was oxidized with MCPBA, and treated with 1-chloroethoxycarbonyl chloride to give 3-(4-chlorobenzenesulfinyl)azetidine. Reaction of the latter with [(S)-1-(tert-butyldiphenylsilanyloxymethyl)-3-iodopropyl]carbamic acid tert-Bu ester gave [(S)-1-(tert-butyldiphenylsilanyloxymethyl)-3-[3-(4-chlorophenylsulfinyl)azetidin-1-yl]propyl]carbamic acid tert-Bu ester. The latter was desilylated, then treated with TFA to give (S)-2-amino-4-[3-(4-chlorobenzenesulfinyl)azetidin-1-yl]butan-1-ol. Reaction of the latter with 3,5-dimethoxyphenyl isocyanate resulted in 1-[(S)-3-[3-(4-chlorobenzenesulfinyl)azetidin-1-yl]-1-hydroxymethylpropyl]-3-(3,5-dimethoxyphenyl)urea. The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).COA of Formula: C9H11Cl2NO

The Article related to inflammatory allergic disease treatment azetidine derivative preparation, azetidine derivative preparation ccr3 receptor antagonist, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.COA of Formula: C9H11Cl2NO

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On August 6, 2015, Bogdan, Andrew; Cowart, Marlon D.; Degoey, David A.; Jinkerson, Tammie K.; Koenig, John R.; Kort, Michael E.; Liu, Bo; Matulenko, Mark A.; Nelson, Derek W.; Patel, Meena V.; Peltier, Hillary; Scanio, Marc J.; Wakefield, Brian D. published a patent.Related Products of 490021-97-1 The title of the patent was Preparation of 6-heteroaryloxy- or 6-aryloxyquinoline-2-carboxamides as sodium channel blockers. And the patent contained the following:

The invention is related to the preparation of title compounds I [R1 = (un)substituted Ph, 5-6 membered heteroaryl; R2 = H, alkyl, alkoxyalkyl, etc.; R3 = H, alkenyl, haloalkyl, etc.; or R2NR3 = (un)substituted 4-8 membered monocyclic heterocycle, 6-11 membered bicyclic heterocycle, 10-12 membered tricyclic heterocycle, 7-11 membered spirocyclic heterocycle or 8-11 membered bicyclic heteroaryl comprised of a monocyclic heterocycle fused to a monocyclic heteroaryl], pharmaceutically acceptable salts, esters, amides, and radiolabeled forms that are sodium channel blockers useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. The invention is also related to pharmaceutical compositions containing I, and methods for using such compounds and compositions Thus, II was prepared by a multi-step synthesis starting from quinoline-2,6-diol. II was active in FRET-based membrane potential assays for human sodium channels Nav1.7 and Nav1.8. The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).Related Products of 490021-97-1

The Article related to quinolinecarboxamide heteroaryloxy aryloxy preparation sodium channel blocker pain, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Related Products of 490021-97-1

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On July 6, 2006, Brohm, Dirk; Diedrichs, Nicole; Huebsch, Walter; Schneider, Dirk; Froehlen, Britta-Nicole; Gerdes, Christoph; Gnoth, Mark Jean; Perzborn, Elisabeth; Voehringer, Verena published a patent.Category: chlorides-buliding-blocks The title of the patent was Preparation of azetidinylpyrazolines as anticoagulation agents. And the patent contained the following:

Title compounds I [X = (CH2)m; m = 0-3; Y = (CH2)n; n = 0-3; R1 = tetramic acid, NR5R6, etc.; R2 = Me, cycloalkyl, Ph, etc.; R3 = substituted Ph, thienyl; A = bond, O; R5 = H, Me, Et, etc.; R6 = H, Me, Et, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, N-acylation of 3-propylazetidine with phenol ester II afforded azetidinylpyrazoline III in 72% yield. In protease activated receptor 1 assays, 6-examples of compounds I exhibited IC50 values ranging from 14-395 nM. The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).Category: chlorides-buliding-blocks

The Article related to azetidinylpyrazoline preparation protease activated receptor par1 anticoagulation agent, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Category: chlorides-buliding-blocks

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On August 25, 2011, Bregman, Howard; Buchanan, John L.; Chakka, Nagasree; Dimauro, Erin F.; Du, Bingfan; Nguyen, Hanh Nho; Zheng, Xiao Mei published a patent.Safety of 3-(4-Chlorophenoxy)azetidine hydrochloride The title of the patent was Preparation of aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain. And the patent contained the following:

The present invention provides compounds I [X = NH, NMe, O, S; S, T and U = CR3, N; A = (hetero)aryl; R1 = H, alkyl, haloalkyl, etc.; R11 = H or alkyl; R2 = H, alkyl, aryl, etc.; R3 = H, halo, alkyl, etc.; R4 = H, alkyl, halo, etc.; R5 = H, alkyl, (hetero)aryl; R6 = (un)substituted (hetero)aryl, heterocyclyl, cycloalkyl, etc.; or NR5R6 = (un)substituted heteroaryl, heterocyclyl, bridged heterocyclyl, spiroheterocyclyl] that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. over three-hundred compounds I were prepared and formulated. thus, reacting 2,4-dichloro-1,3,5-triazine with 3-amino-2-methylbenzamide followed by treating the resulting 3-(4-chloro-1,3,5-triazin-2-ylamino)-2-methylbenzamide with 1-(3,4-dimethylphenyl)piperazine afforded II. compounds I were tested on human Nav1.7 expressed stably in 293 cells (data given). also provided are pharmaceutical compositions containing compounds I and processes for preparing such compounds The experimental process involved the reaction of 3-(4-Chlorophenoxy)azetidine hydrochloride(cas: 490021-97-1).Safety of 3-(4-Chlorophenoxy)azetidine hydrochloride

The Article related to aryl carboxamide amide preparation analgesic sodium channel inhibitor, voltage gated sodium channel blocker aryl carboxamide amide preparation, chronic pain treatment aryl carboxamide amide preparation and other aspects.Safety of 3-(4-Chlorophenoxy)azetidine hydrochloride

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics